We have known for a while that #LongCOVID pathobiology for many involves reactivation of various herpesviruses. As we continue to validate this it is great to see this work coming out in collaboration with @VirusesImmunity’s incredible team. Here we


1/medrxiv.org/content/10.648… show that DNA levels of HHV6, a very common form of herpesvirus that infects most people in early childhood, were found in the saliva of people with #LongCOVID. Furthermore, we saw that these DNA levels were positively associated with overall LC symptom burden. Meaning, the
2/

Excited to work with @Invivyd to get this out. One of the most common questions I get from people in the #LongCOVID community are about vaccination alternatives. People still want to protect themselves from SARS-CoV-2 infection but many experience
1/medrxiv.org/content/10.648… systemic adverse effects from vaccination. This is an inconvenient fact of vaccination that leads to many feeling gaslit and unable to protect themselves. Our goal is always to provide people with as many tools as possible so that they always have an array of choices when
2/

Excited to finally get this one out in @Nature_NPJ! In the largest study of its kind to date, we used data from the @visible_health platform to answer a simple question: can we predict symptom fluctuations and crashes from both the physiological and

1/nature.com/articles/s4174… patient-reported data? The answer to this question is yes. Not perfectly, but actually quite well. A few important takeaways:
1) Just as we have seen previously in people living with chronic pain, the ability to predict symptom flares and crashes in ppl with #LongCOVID,
2/

I want to thank everyone for the interest in this work that we completed in a #LongCOVID cohort with this novel device. I always appreciate feedback and want to thank folks for holding me accountable to a high standard of communication. To that end, I want to re-clarify this
1/

https://twitter.com/putrinolab/status/2036525558398427152

thread: this was a safety/feasibility trial which means that our primary endpoints were related to safety and feasibility. In the paper, we state clearly that we hit those endpoints: no device-related adverse events and 100% adherence to the protocol in all participants. That
2/

Excited to get this out in preprint: triple-blind, placebo-controlled microtesla magnetic therapy (MMT) is safe, feasible and effective in reducing cognitive impairment in people with #LongCOVID. I get excited about interventions for cognitive symptoms

1/medrxiv.org/content/10.648… as they can be so disabling and frightening because you don't know if the symptoms are going to be permanent. This paper makes us feel hopeful that Long COVID cognitive impairment related to neuroinflammation is something that is treatable. This was a first-in-human safety-
2/

Proud to have worked with the brilliant @drmfreire on this new study looking into spike protein in #LongCOVID. The most important part of this study that doesn't just look for spike protein in folks with LC and healthy controls, but it also uses a technique called
1/

https://twitter.com/drmfreire/status/2032475776814395407

spatial transcriptomics to better understand how spike protein might be interacting with the tissue around it. Here's what is interesting about this trial: lots of gut tissue samples, in both healthy controls and #LongCOVID showed evidence of persistent spike protein. However,
2/

Crucial paper published Friday that deserves much more attention in the #LongCOVID world: .

TLDR: 13/15 immunocompromised patients who had chronic COVID infections (>200 days) cleared the virus in under 2 weeks when given combo antivirals/monoclonals

1/nature.com/articles/s4159… The caveat: yes these were cancer patients who were severely immunocompromised, and the "haters" are going to say that it isn't appropriate to draw parallels between this patient group and folks with #LongCOVID.

That's incorrect.

It is perfectly acceptable to draw such

2/

Great win early in the year to receive notification that our case series looking into Dr Pridgen’s Valacyclovir, Celecoxib and Paxlovid protocol seems to really help some folks with #LongCOVID. This paper is a start, not the be-all and end-all:


1/frontiersin.org/journals/immun… It is a small, open-label case series, but there are some interesting things that are worth noting that give me hope that what we are seeing is real and will hold up in a larger trial
1) People got to choose between Val/Cel only (called ‘IMC-2’ in the paper) and Val/Cel + Pax
2/

Wishing everyone a happy new year and we will be forging ahead in 2026 with renewed energy to find answers for people living with #LongCOVID, #MECFS, chronic #lyme and other infection-associated chronic conditions and illnesses. Speaking for myself, here are some questions I
1/ hope we can answer this year. Since it isn’t my first time on the internet let me explicitly state: there are other questions that we will be chasing equally aggressively, but these are the ones that I most want to answer to up-level my own understanding of the scientific and
2/

Respectfully @jonstewart, you were wrong on the @weeklyshowpod to mock people who mask. ICYMI: there are tens of millions of Americans who have been disabled by #LongCOVID and must do everything in their power to prevent further infections that make them vulnerable to further
1/ worsening of their symptoms. There are countless millions more who are immunocompromised or love someone who is and must therefore mask to protect themselves from a virus that continues to spread without mitigation due to its novel ability amongst viruses to persist in the
2/

This paper was published last week about #COVID, #LongCOVID and its parallels. First, despite the provocative title, I urge people to read the paper the whole way through, rather than making assumptions about what you presume the paper will conclude.
1/ajpmfocus.org/article/S2773-… The purpose of the paper is to answer a direct question: Is use of the term "Airborne AIDS":
a) justifiable
b) overly provocative and wrong, or
c) is the truth somewhere in between

The paper (IMO) does a good job of exploring the available literature that we have to answer
2/

Great to see this published and out there. It's a simple paper that shows us that folks with #LongCOVID, #MECFS and other complex chronic illnesses can benefit from using symptom tracking apps like @visible_health, designed FOR patients, BY patients.


1/frontiersin.org/journals/digit… Let's break down some of the findings:
- The survey was sent to 2636 active users on the Visible platform, and 1301 responded. This translates to a roughly 50% response rate, which is very high for app-based consumer surveys (average usually sits around 5-10%), which means
2/

A few days out from #UNGA80, I wanted to reflect on the session we took part in and the media responses since. Mount Sinai was one of the 150 organizations that signed the global pledge to advocate for healthy indoor air. The event itself featured four panels of speakers who
1/ came from all walks of life, all ages, all levels of experience, expert academics and people with boots on the ground experience in helping communities and all came to the same conclusion: access to clean air is not just a priority, it is a fundamental human right. Violet also
2/

Hi there, thanks for reaching out. Sorry to hear about your recent COVID infection. If you don't have pre-existing Long COVID, infection-associated chronic illness then there are some basic guidelines that exist to slowly ease your way back to exercise. First, and most
1/

https://twitter.com/ChristinaAuria/status/1967662463505387752

unambiguously: do NOT rush back to exercise if you're sick or symptomatic at all. General guidelines for viral illnesses typically will encourage waiting at least 10 days from your initial infection-onset, PLUS at least 3 symptom-free days before resuming any exercise that
2/

Happy to share some new #LongCOVID data that went to pre-print today. Before we begin breaking this down, one caveat: this work MUST be validated by a well-powered placebo-controlled randomized controlled trial before we can get too excited, but this is

1/researchsquare.com/article/rs-750… an exciting first step and something that we hope will deepen our understanding of use of combination antivirals in the #LongCOVID community. A bit of background about how we got here: in early 2025 our team was part of a consortium that published a roadmap for targeting viral
2/

I was asked to respond to this. Honestly I don't pay too much attention to this account because I prefer to spend energy on people and things that build community in #LongCOVID and IACI rather than curating divisiveness, but this shouldn't go without rebuttal so here we go.
1/

https://twitter.com/sunsopeningband/status/1958887804462612574

First up, as someone who works in innovation, I *love* unpopular opinions - that's where alternative points of view live that allow us to look at a problem in a different way. But IT IS disingenuous to dress up an *uninformed* or *misleading* opinion as "unpopular" - that's
2/

This is an issue that has been coming up today from various folks and I want to address it. As I said when we launched the manual, this is the beginning of a conversation, not the "final word". I also want to say that reading it with 20/20 hindsight, I understand why this 1/

https://twitter.com/x3r0gx4/status/1956352433799450957

language has been inflammatory to members of the community, because it the feedback I have received is that it "feels like we're trying to say that exercise is curative even with PEM, without saying the word exercise". I regret that this was the impression that our wording
2/

Really proud of my team for getting this out. It has been a heavy lift. When we opened the Cohen Center for Recovery from Complex Chronic Illness, we wanted to create a place that could provide the very best of care for people with #LongCOVID, #MECFS,
1/

beckershospitalreview.com/quality/patien… chronic tick- and vector-borne illness and other infection associated chronic illnesses. We wanted to make sure that this could be done billing codes that are covered by insurance, and most importantly, we did *not* want to become a destination clinic - we wanted to create a
2/

I was asked about my opinion on this recent study into #MECFS and I wanted to share here as well. First and foremost, sincere congratulations to the research team for some stellar work. I will never stop cheering for groups that are working to uncover the biological 1/

https://twitter.com/mecfsskeptic/status/1953353139639177370

underpinnings of these illnesses. Next, I think that the study is credible and well-conducted with a great, big data set that agrees with other studies in the space that have shown that, yes - people with #MECFS, #LongCOVID () and perhaps even other 2/medrxiv.org/content/10.110…

I'm glad to see @BuzzFeed running educational content about tick- and vector-borne illness like #lyme, but I must disagree with Dr Shapiro, who is quoted in this article, that an infected tick *has* to be on for 24-36 hrs to transmit Lyme Disease. The
1/
buzzfeed.com/jillianwilson/… public should be aware that transmission of Borrelia Burgdorferi, the bacteria that causes #Lyme disease can happen sooner than 24-36 hours. In fact, nymph ticks (much harder to spot than full-grown) have been known to transmit Lyme to a host in under 12 hours. Furthermore,
2/

In honor of #PrideMonth2025, I just wanted to take a moment to discuss the crucial role of intersectionality, gender and inclusion in research, specifically as it relates to our research involving #LongCOVID, #MECFS, chronic #lyme and other complex chronic illnesses. As we 1/ work to understand these illnesses, we must often contend with the fact that they are characterized by a diverse array of symptoms that cause dynamic disability (fluctuating severity of symptoms that can lead to fluctuating levels of disability). As we've learned, so many 2/